ProCE Banner Activity

Helping Patients With HF Manage Side Effects of SGLT2 Inhibitors

Clinical Thought

In this commentary, expert faculty discuss practical considerations for the management of patients using SGLT2 inhibitors such as diagnosis and mitigation of genital urinary infections, urinary tract infections, and ketoacidosis.

Released: October 27, 2023

Share

Faculty

Javed Butler

Javed Butler, MD, MPH, MBA

President
Baylor Scott and White Research Institute
Dallas, Texas
Distinguished Professor of Medicine
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Disclosure

Primary Author

Javed Butler, MD, MPH, MBA

President
Baylor Scott and White Research Institute
Dallas, Texas
Distinguished Professor of Medicine
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Javed Butler, MD, MPH, MBA: consultant/advisor/speaker: Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element Science, Imbria, Impulse Dynamics, Innolife, Inventiva, Janssen, Lilly, LivaNova, Lexicon, Medtronics, Merck, Novartis, Novo Nordisk, Occlutech, Pfizer, Pharmacosmos, Roche, Sequana, SQ Innovation, Vifor.